[
  {
    "ts": null,
    "headline": "Insulet Corporation (PODD) Sees Higher 2025–2026 Revenue and Operating Margins, Says Canaccord",
    "summary": "Insulet Corporation (NASDAQ:PODD) ranks among the best medical device stocks to invest in. Canaccord Genuity maintained its Buy rating on Insulet Corporation (NASDAQ:PODD) and boosted its price target from $353 to $399 on September 29. In order to incorporate the latest investor conferences and revised revenue guidance into its model, the firm marginally raised its […]",
    "url": "https://finnhub.io/api/news?id=58cc5fe0a62d0c59298919395fda3d0d37e1c67c9a54d0b2f2ca231031282895",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760956259,
      "headline": "Insulet Corporation (PODD) Sees Higher 2025–2026 Revenue and Operating Margins, Says Canaccord",
      "id": 137174866,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "Insulet Corporation (NASDAQ:PODD) ranks among the best medical device stocks to invest in. Canaccord Genuity maintained its Buy rating on Insulet Corporation (NASDAQ:PODD) and boosted its price target from $353 to $399 on September 29. In order to incorporate the latest investor conferences and revised revenue guidance into its model, the firm marginally raised its […]",
      "url": "https://finnhub.io/api/news?id=58cc5fe0a62d0c59298919395fda3d0d37e1c67c9a54d0b2f2ca231031282895"
    }
  }
]